COVID-19 (Coronavirus) Update
Vaccine Updates | COVID-19 Information | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

21 results for "Cancer" and "Thoracic Cancers"

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
Protocol No
PFIZER-B7461009
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
Breast Cancers

Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events

This study is being done to answer the following questions: Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively? To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...
Protocol No
ALLIANCE-A151804
Sub Category
Gastrointestinal Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Sub Category
Gynecologic Cancers
Prostate and Urologic Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Head and Neck Cancers
Gastrointestinal Cancers

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.
Protocol No
NRG-CC003
Sub Category
Brain and Spine Cancers
Thoracic Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Protocol No
ACCRU-SC-1601
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Eye/Orbital Cancers
Endocrine Cancers
Breast Cancers
Brain and Spine Cancers

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC)

Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. Sometimes this natural immune system response stops, and the cancer is not killed by the immune system. Research has shown that, in some patients, cancer cells and immune cells start to express signals that stop the body’s immune system from killing the cancer. New drugs being developed are designed to block these signals and to increase the immune response. Durvalumab and tremelimumab are two of these drugs. Both drugs are antibodies (proteins that are produced by the body’s defense system). Durvalumab given by itself or with tremelimumab may boost the ability of your immune system to detect and fight cancer. Each of these drugs targets a different signal. Durvalumab targets a signal on cancer cells called Programmed Cell Death Ligand 1 (PD-L1) and tremelimumab targets a signal on immune cells called Cytotoxic T-Lymphocyte-associated Antigen 4 (CTLA-4). It is hoped that by blocking these signals, the immune cells will once again be able to prevent or slow down cancer growth.

The vaccine, BI 1361849, also works by stimulating the body’s immune system to fight and destroy cancer cells. There are six different ingredients in the vaccine that each produce a different antibody response to tumor cells. The vaccine is given through an injection into your skin.
Protocol No
LUDWIG-LUD2014-012-VAC
Sub Category
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer.
Protocol No
NGM-18-0402
Sub Category
Gastrointestinal Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Share This: